| Titre |
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors |
| Protocole ID |
CA244-0001 |
| ClinicalTrials.gov ID |
NCT06618287 |
| Type(s) de cancer |
Tumeurs solides |
| Phase |
Phase I-II |
| Type étude |
Clinique |
| Médicament |
BMS-986507 avec osimertinib et BMS-986507 avec pembrolizumab |
| Institution |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
| Ville |
Montréal |
| Investigateur(trice) principal(e) |
Dre Marie Florescu
|
| Coordonnateur(trice) |
|
| Statut |
 Actif en recrutement |
| Critètes d'éligibilité |
- Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
- Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- Participants must have a life expectancy of at least 3 months at the time of the first dose.
|
| Critètes d'exclusion |
- Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
- Participants must not have any untreated symptomatic central nervous system (CNS) metastases.
- Participants must not have a history of serious recurrent infections.
- Participants must not have a history of severe heart disease.
- Other protocol-defined Inclusion/Exclusion criteria apply.
|
Groupe d'étude en oncologie du Québec